Form 4: Vir Biotechnology Director Saira Ramasastry Boosts Stake with RSU Grant and Stock Option Acquisition

Vir Biotechnology, Inc. Director Saira Ramasastry acquired 8,000 restricted stock units and 16,000 stock options, signaling increased insider ownership.

Summary

• Director Saira Ramasastry of Vir Biotechnology, Inc. acquired 8,000 restricted stock units (RSUs) on May 30, 2025, pursuant to the Issuer's Equity Incentive Plan.
• These 8,000 RSUs were acquired at a price of $0 and are scheduled to vest in full on May 30, 2026.
• Following this transaction, Ms. Ramasastry beneficially owns 22,619 shares of common stock.
• Additionally, Ms. Ramasastry acquired 16,000 stock options on May 30, 2025, with an exercise price of $4.94 per share.
• These stock options will vest and become exercisable in full on May 30, 2026, and have an expiration date of May 29, 2035.
• After this transaction, Ms. Ramasastry beneficially owns 16,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The acquisition of equity by a director, even if through grants, generally signals alignment of interests and potential confidence in the company's future, which is a positive indicator for investors. However, it's a routine compensation event rather than a direct investment of personal capital.

Positives

• Increased insider ownership by a Director, which can signal confidence in the company's future prospects.
• The acquisition of RSUs and stock options aligns the Director's interests with long-term shareholder value.
• The transactions are part of the Issuer's Equity Incentive Plan, indicating a structured approach to executive compensation and retention.

Negatives

• The acquired RSUs and stock options are subject to a vesting schedule, meaning they are not immediately exercisable or fully owned.
• The RSUs were acquired at a $0 price, which is typical for grants but represents no direct cash investment by the director at the time of grant.

Risks

• The value of the RSUs and stock options is dependent on the future performance of Vir Biotechnology's stock price.
• The vesting of both the RSUs and stock options is contingent upon continued service until May 30, 2026.

Future Outlook

The acquired restricted stock units and stock options are scheduled to vest in full on May 30, 2026, indicating a future milestone for the director's equity compensation. The stock options have a long-term expiration date of May 29, 2035.

Industry Context

This Form 4 filing details an individual insider transaction, which is a routine disclosure for publicly traded companies, particularly in the biotechnology sector where equity compensation is a common practice to attract and retain talent. It does not provide broader industry trends or competitive analysis.

Corporate Governance

Related Party Transactions

• The acquisition of 8,000 Restricted Stock Units and 16,000 Stock Options by Director Saira Ramasastry from Vir Biotechnology, Inc. constitutes a related party transaction as it involves an executive officer/director and the company.

Stakeholder Impact

• Shareholders: The increased equity ownership by a director may be viewed positively as it aligns management's interests with shareholder value creation. It can signal confidence in the company's long-term prospects.
• Employees: The equity incentive plan, under which these grants were made, is a common tool for attracting and retaining talent, potentially benefiting other employees through similar programs.

Next Steps

• The 8,000 Restricted Stock Units are scheduled to vest in full on May 30, 2026.
• The 16,000 Stock Options are scheduled to vest and become exercisable in full on May 30, 2026.

Key Dates

Keywords

Vir Biotechnology, VIR, SEC Form 4, Insider Trading, Restricted Stock Units, RSU, Stock Options, Equity Incentive Plan, Director Compensation, Biotechnology, Executive Compensation